Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease
| Autor: | Nathalie Demoulin, Michel P. Hermans, Michel Jadoul, Johann Morelle, Benoit Buysschaert, Selda Aydin |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism 030232 urology & nephrology Gastroenterology Diabetic nephropathy 03 medical and health sciences Lactones 0302 clinical medicine Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Humans 030212 general & internal medicine Aged 80 and over Orlistat Hyperoxaluria medicine.diagnostic_test business.industry General Medicine medicine.disease Diabetes Mellitus Type 2 Lipase inhibitors Albuminuria Kidney Diseases Renal biopsy Anti-Obesity Agents medicine.symptom business Enteric Hyperoxaluria medicine.drug Kidney disease |
| Zdroj: | Diabetesmetabolism. 42(1) |
| ISSN: | 1878-1780 |
| Popis: | Aim This report describes a case of kidney failure secondary to orlistat, a lipase inhibitor commonly used in the treatment of obesity. Case report An 80-year-old man with type 2 diabetes who was being treated with orlistat developed rapidly progressive kidney failure. Low-grade albuminuria argued against diabetic nephropathy. Renal biopsy showed tubulointerstitial nephritis associated with numerous calcium oxalate crystals. Enteric hyperoxaluria was attributed to the orlistat treatment. The latter was stopped and the patient received calcium supplements. Six months after orlistat withdrawal, oxaluria was normalized and kidney function stabilized. Conclusion Oxalate nephropathy may result from hyperoxaluria secondary to orlistat treatment. This suggests that kidney function and oxaluria be closely monitored in patients taking orlistat. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect